Seagen secures a speedy FDA review on Tukysa as Merck buyout talks reportedly stall
After rumors of stalled buyout talks between Merck and Seagen, perhaps a new Tukysa indication could reignite interest.
The FDA has granted Tukysa a priority review in combination with Genentech’s Herceptin for second-line HER2-positive metastatic colorectal cancer, the company revealed on Monday. The decision comes just a couple of months after Seagen uncorked the full Phase II results at ESMO, boasting a notable improvement in overall survival from the last readout.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.